In a recent report where immunotherapy was used for patients with advanced hepatocellular carcinoma (HCC), PARG inhibition was shown to have a synergistic effect with anti-programmed cell death 1 (PD1) therapy (21). This evidence concerns the gene PARG and hepatocellular carcinoma.